LEO Pharma Posts 9% CER Revenue Growth in Q1 2026, Bolsters Rare Dermatology Pipeline
Event summary
- LEO Pharma reported Q1 2026 revenue growth of 9% at constant exchange rates (CER), driven by a 43% CER increase in strategic dermatology brands Anzupgo®, Spevigo®, and Adtralza®/Adbry®.
- Operating profit improved with adjusted EBITDA rising 12% to DKK 610 million, while free cash flow reached DKK 336 million.
- The company acquired Replay’s gene therapy platform for rare genetic skin diseases and secured FDA acceptance for Anzupgo®’s label expansion in adolescent hand eczema.
- China’s NMPA approved Enstilar® for plaque psoriasis, expanding access to 6 million adults in the country.
The big picture
LEO Pharma’s Q1 2026 performance underscores its strategic focus on dermatology innovation, particularly in rare diseases, as it competes in a market increasingly dominated by specialty treatments. The acquisition of Replay and regulatory milestones for Anzupgo® and Enstilar® signal a push toward higher-margin, niche therapies, aligning with broader industry trends toward precision medicine. The company’s ability to balance growth investments with profitability will be critical as it navigates a competitive landscape and evolving regulatory environments.
What we're watching
- Pipeline Execution
- Whether LEO Pharma can sustain the momentum of its late-stage dermatology candidates, particularly Anzupgo®, following FDA acceptance for review.
- Commercial Scale
- The pace at which the company can integrate and commercialize Replay’s gene therapy platform to address rare genetic skin diseases.
- Profitability Trade-offs
- How increased spending on development activities post-Replay acquisition will impact the adjusted EBITDA margin outlook of 15-18% for 2026.
Related topics